Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype

Pharmacological Reports

Volumn 57, Issue 1, 2005, Pages 124-127

  Rybakowski, Janusz K ^a   Suwalska, Aleksandra ^a   Czerski, Piotr M ^a   Dmitrzak Weglarz, Monika ^a   Leszczynska Rodziewicz, Anna ^a   Hauser, Joanna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

5 HTTLPR; Lithium prophylaxis; Pharmacogenetics; Serotonin transporter

Indexed keywords

LITHIUM CARBONATE; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PROMOTER REGION; PROPHYLAXIS; SEROTONINERGIC SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 18044379898     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Anguelova M, Benkelfat C, Turecki G: A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry, 2003, 8, 574-591.
2. Arias B, Catalan R, Gasto C, Guitierez B, Ananas L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow-up study. J Clin Psychopharmacol, 2003, 23, 563-567.
3. Caspi A, Sudgen K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 2003, 18, 291-293.
4. Del Zompo M, Ardan R, Palmas MA, Bocchetta A, Reina A, Piccardi MP: Lithium response: association study with two candidate genes. Mol Psychiatry, 1999, 4, Suppl 1, S66-S67.
5. Hanser J, Leszczynska A, Samochowiec J, Czerski PM, Ostapowicz A, Chlopocka M, Horodnicki J et al.: Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. Eur Psychiatry, 2003, 18, 129-132.
6. Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R: Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord, 1999, 54, 87-96.
7. Lesch KP, Hiels A: Serotonergic gene transcriptional control regions: targets for antidepressant drug development. Int J Neuropsychopharmacol, 2000, 3, 67-79.
8. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 1988, 16, 1215.
9. Muller-Oerlinghausen B: Lithium long-term treatment -does it act via serotonin? Pharmacopsychiatry, 1985, 18, 214-217.
10. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush JA, Schaztzberg AF, Ninan PT et al.: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA, 2003, 100, 14293-14296.
11. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE: Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry, 1991, 159, 123-129.
12. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E: Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res, 1999, 33, 371-377.
13. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E: Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J, 2001, 1, 71-77.
14. Serretti A, Lorenzi C, Lilli R, Smeraldi E: Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res, 2000, 34, 89-98.
15. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the serotonin transporter and antidepressant efficacy of fluvoxamine. Mol Psychiatry, 1998, 3, 508-511.
16. Stefos G, Bauwens F, Staner L, Pardoen D, Mendlewicz J: Psychosocial predictors of major affecfive recurrences in bipolar disorder: a 4-year longitudinal study of patients on prophylactic treatment. Acta Psychiatr Scand, 1996, 93, 420-426.
17. Turecki G, Grof P, Grof E, D'Souza V, Lebuis L, Marineau C, Cavazzoni P et al.: Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry, 2001, 6, 570-578.
18. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol, 2000, 20, 105-107.